Reexpression of hnf4a to alleviate cancer-associated cachexia
AssigneesYeda Research and Development Co. Ltd., Technion Research & Development Foundation Limited
InventorsAyelet EREZ, Omer GOLDMAN, Emma HAJAJ, Avi SCHROEDER
Life of this patent
Estimating the term…
Abstract
Methods of predicting clinical outcome in a subject suffering from cancer, detecting non-liver cancer in a subject, and methods of treating or preventing cancer or cancer-associated cachexia are provided. Synthetic lipid nanoparticles encapsulating an mRNA encoding for HNF4A and composition comprising same are also provided.
Claims21
-31. (canceled)
A method of detecting a non-hepatic cancer in a subject or predicting a clinical outcome in a subject suffering from non-hepatic cancer, the method comprising measuring function of the urea cycle in said subject, wherein decreased urea cycle function as compared to urea cycle function in a healthy control indicates said subject suffers from a non-hepatic cancer or indicates a worse clinical outcome for a subject suffering with non-hepatic cancer as compared to a subject without decreased urea cycle function, thereby detecting non-hepatic cancer or predicting a clinical outcome in a subject suffering from non-hepatic cancer, further comprising administering to a subject identified with said worse clinical outcome and determined to have non-hepatic cancer, at least one therapeutic agent selected from:
- an anti-IL6 blocking antibody, an ERK inhibitor, a STAT3 inhibitor and an agent capable of increasing expression of HNF4A in a liver of said subject.
A synthetic lipid nanoparticle (LNP) comprising encapsulated therein an mRNA encoding for HNF4A, wherein:
- a. said lipid nanoparticle comprises SM-102 lipid, cholesterol, DOPE, and DMG-PEG;
- b. said mRNA comprises or consists of a sequence of SEQ ID NO:
- 10 or 12 or a sequence comprising at least 85% identity thereto and encoding HNF4A and a poly-A tail;
- or
- c. both.
A method of treating a non-hepatic cancer in a subject in need thereof, the method comprising administering to said subject an agent capable of increasing expression of HNF4A in a liver of said subject or of preventing cancer-associated cachexia in a subject in need thereof, the method comprising administering to said subject a composition comprising at least one agent selected from:
- an anti-IL6 blocking antibody, an ERK inhibitor, a STAT3 inhibitor and an agent capable of increasing expression of HNF4A in a liver of said subject, thereby treating said non-hepatic cancer in a subject.
Dependencies are inferred from the claim text.